Latest Depression News

InhaleRx Limited has successfully closed its entitlement offer and placement, raising $857,730 to support the clinical development of inhaled treatments targeting cancer pain and mental health conditions.

Actinogen Medical has finalized enrollment and begun treatment of all 246 participants in its XanaMIA Phase 2b/3 Alzheimer’s trial, with topline results expected in November 2026. The oral drug Xanamem targets brain cortisol to potentially slow disease progression.

TrivarX Limited has reported compelling clinical trial results demonstrating its single-lead ECG algorithm’s high sensitivity in detecting major depressive episodes among US veterans, marking a significant step in objective mental health screening.

InhaleRx advances its clinical pipeline with a new oral treatment for resistant depression and plans a strategic rebrand to Nexalis Therapeutics, signaling a broader focus beyond inhaled therapies.

InhaleRx Limited has secured $427,500 from an initial tranche of its $1 million capital raise, issuing 17.1 million shares to support its inhaled therapies targeting pain and mental health conditions.

State Gas Limited has raised $3.2 million through convertible notes issued at a 33% premium, alongside a $0.5 million director debt conversion, to accelerate pre-development of its Rolleston West coal seam gas project following a maiden 2P reserve certification.

InhaleRx has boosted its funding facility by $12.6 million to accelerate clinical trials of SRX-25, a novel oral treatment for Treatment-Resistant Depression. This brings total available capital to $52.3 million, positioning the company for pivotal Phase III studies.

InhaleRx Limited has introduced SRX-25, an oral fixed-dose combination therapy targeting Treatment-Resistant Depression, aiming to improve patient access and adherence. The company also secured $1 million in capital to advance clinical development and plans a strategic rebrand.

Little Green Pharma Ltd reported a 9.6% revenue increase to $19.2 million and slashed its net loss by 73% in the half-year ending September 2025, driven by strong growth in European medicinal cannabis markets.

Mastermyne’s FY2025 AGM reveals resilience amid sector headwinds, operational disruptions, and legal proceedings, while positioning for growth with new leadership and contracts.

Emyria Limited is fast-tracking its national rollout of Empax mental health clinics, backed by a strong $8 million institutional placement and new dual-payer funding pathways.

Biotron Limited has launched a $1.5 million non-renounceable rights issue to fund its strategic acquisition of Sedarex Limited and support ongoing drug development programs. The capital raise follows shareholder approval and aims to diversify Biotron’s portfolio with a next-generation general anaesthetic.